This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergsland, E. Articles by Dickler, M. N. Search for Related Content PubMed PubMed Citation Articles by Bergsland, E. Articles by Dickler, M. N.

Maximizing the Potential of Bevacizumab in Cancer Treatment

^a Department of Medicine, University of California, San Francisco, California, USA; ^b Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Emily Bergsland, M.D., Department of Medicine, University of California, San Francisco, 1600 Divisidero Street, 4th Floor, San Francisco, California 94115, USA. Telephone: 415-353-9888; Fax: 415-353-9959; e-mail: emilyb{at}medicine.ucsf.edu

Promising results have been obtained with bevacizumab (Avestin^TM; Genentech, Inc.; South San Francisco, CA) in clinical trials in patients with a range of solid tumors; however, to maximize the potential of this agent, further research is needed to clarify a number of important issues. These include the optimization of bevacizumab dosage and schedule of administration, the potential value of this agent in combination with other treatment modalities like chemotherapy and radiation, the management of toxicities, and the selection of patients most likely to benefit from treatment. Intriguing results from two recent phase III trials highlight the need for a better understanding of the best ways to incorporate bevacizumab into clinical practice. Ultimately, maximizing the potential value of this agent may require a more thorough understanding of bevacizumab’s mechanism of action and the pathways mediating resistance.

Key Words. Solid tumors • Bevacizumab • Chemotherapy • Clinical trials

This article has been cited by other articles:

				M. H.G. Langenberg, C. M.L. van Herpen, J. De Bono, J. H.M. Schellens, C. Unger, K. Hoekman, H. E. Blum, W. Fiedler, J. Drevs, F. Le Maulf, et al. Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors J. Clin. Oncol., December 20, 2009; 27(36): 6152 - 6159. [Abstract] [Full Text] [PDF]

				J. Kanter, S. Y. Khan, M. Kelher, L. Gore, and C. C. Silliman Oncogenic and Angiogenic Growth Factors Accumulate during Routine Storage of Apheresis Platelet Concentrates Clin. Cancer Res., June 15, 2008; 14(12): 3942 - 3947. [Abstract] [Full Text] [PDF]

				A. M.P. Omuro, S. Faivre, and E. Raymond Lessons learned in the development of targeted therapy for malignant gliomas Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919. [Abstract] [Full Text] [PDF]

				H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]

				N. H. Fernando and H. I. Hurwitz Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 11 - 18. [Abstract] [Full Text] [PDF]

				H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF]

				H. S. Rugo Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data Oncologist, June 1, 2004; 9(suppl_1): 43 - 49. [Abstract] [Full Text] [PDF]